La prise en charge des déficits moteurs de la mimique faciale est complexe et nécessite un suivi sur le long terme. Il existe de nombreuses techniques d’évaluation de la mimique faciale déficitaire avec des degrés variables de sensibilité. Cependant, la plupart de ces techniques sont manuelles et qualitatives (testing musculaire et scores cliniques). Elles conduisent donc à des mesures subjectives et peu reproductibles dans le temps. Ces techniques d’évaluation reposent en outre sur l’appréciation de l’évaluateur qui est une source importante de biais. Ainsi, l’apport d’un outil de mesure objectif pour quantifier un déficit et optimiser le suivi et la prise en charge médicale, chirurgicale et rééducative des patients apparait comme nécessaire. L’objectif de ce travail de thèse était donc de développer un outil quantitatif permettant d’évaluer les troubles de la mimique faciale. Dans cette perspective, nous avons mis en place un protocole d’analyse du mouvement par motion capture et avons réalisé des mesures sur une population de référence. Une étude descriptive utilisant un système de capture de mouvement en 3 dimensions a été réalisée sur des volontaires sains (n = 30) âgés de 20 à 30 ans. Le système de capture du mouvement était constitué de 17 caméras optoélectroniques T160 et de 2 caméras vidéo Bonita (Vicon™). Les mouvements étudiés étaient : la fermeture « simple » (non forcée) des paupières, la fermeture forcée des paupières, la protrusion labiale sur le son « o » [o], la protrusion labiale sur le son « pou » [pμ], et un sourire volontaire découvrant les dents. Lors de ces mouvements, nous avons enregistré et analysé le déplacement de 111 marqueurs réfléchissants de 1.5mm placés sur la face des sujets. Pour les cinq mouvements réalisés, nous avons obtenu des données quantitatives. Celles-ci nous ont permis d’identifier les zones d’action pour chacun des mouvements, de mesurer l’amplitude des déplacements et d’obtenir des données comparables dans le temps. Par ailleurs, le protocole mis en place a été évalué et sa réalisation est compatible avec une application clinique. L’analyse de la cinématique de la face est donc une technique appropriée à la clinique qui pourrait faciliter le diagnostic, le suivi et la rééducation des patients. Ce travail a permis de définir des mesures de référence qui constitueront la base d’un outil diagnostic, qu’il convient désormais de mettre en œuvre sur des patients. / The care of facial paralysis is often complex and therefore requires monitoring over the long term. There are many clinical severity scores with varying levels of sensitivity to assess the deficit of facial movement, but most of them are qualitative. The number of assessment methods is an obstacle to monitor patients and treatment evaluation. We need an objective measurement tool to provide reliable measures of resting asymmetry, symmetry of voluntary movement and synkinesis. The aim of this study is to determine if the 3D motion capture of the face is compatible with these clinical criteria. A descriptive study using a 3-dimensional (3D) motion capture system were performed on healthy volunteers (n=30) age from 20 to 30 years. The motion capture system consists of 17 optoelectronic cameras at a frequency of 100Hz. We captured the movements of the face on healthy volunteers. We obtained absolute values: 3D coordinates and relative displacements. These data were free of manual measurements, and the use of 3D motion capture does not impede the facial movement. The average time of capture was less than 10 minutes. The measurements are painless for subjects. Data are collected in a computer and can be easily exported. These results show the feasibility of 3D motion capture of facial movement. The protocol used here could be standardized to be routinely relevant. lt was used in an experimental study to follow up recovery of a facial transplantation. This technique could help to overcome the uncertainty caused by subjective assessment and optimize therapeutic choices.

Genom spatial närvaro i en experimentell medieteknisk filminstallation siktar arbetet på att ge kännedom om det naturliga fenomenet sömnparalys (SP). Det här görs genom en medieteknisk undersökning som blandar mytologi, som tros ha uppstått på grund utav SP, med verkliga fakta om SP. Arbetet resulterade i en animerad film i 3D som presenterades i en filminstallation. Upplevelsen av installationen ska simulera hur det känns att drabbas av fenomenet. Tanken är att deltagarna ska kunna identifiera SP i deras dåtid och framtid och få veta att det är en naturlig process och ej är farligt. Arbetet togs fram genom designperspektiven x for change och edutainment som låg till grund för filminstallationen. / Through immersion in an experimental media technological video installation this work aims to give awareness of the natural phenomenon sleep paralysis (SP). This was done through a research in media technologies that mixes mythology, that is believed to be based on SP, with real facts about SP. The work resulted in a 3D animated movie that was presented in a video installation. The experience is supposed to simulate how it feels to be affected by the phenomenon. The idea was that the participant will be able to identify SP in their past and future and to know that it is a natural process that is not dangerous. The work was done through the design perspectives x for change and edutainment that was the foundation for the video installation.

No description available.

Alzheimer’s disease (AD) is symptomized by amyloid-beta plaques in the brain and accounts for more than 65 percent of dementia cases. Vitamin B12 (cobalamin) deficiency can result in similar cognitive impairment and roughly 15% of the elderly are vitamin B12 deficient. Vitamin B12 deficiency results in the accumulation of toxic methylmalonic acid and homocysteine. Hyperhomocysteinemia is a strong risk factor for AD. To test if vitamin B12 deficiency stimulates amyloid-beta toxicity, Caenorhabditis elegans expressing amyloid-beta in muscle were fed either vitamin B12-deficient OP50-1 or vitamin B12-rich HT115(DE3) E. coli bacteria. Increased amyloid-beta toxicity was found in worms fed the 0P50-1 diet. Supplementation of the OP50-1 diet with vitamin B12 did not rescue the increased C. elegans toxicity. Knockdown of either of the only two C. elegans vitamin B12-dependent enzymes metr-1 or mmmc-1 protected against toxicity. Therefore, vitamin B12 deficiency does not stimulate Alzheimer’s amyloid-beta-mediated toxicity in C. elegans.

This thesis looks at the social, political, and military effects of epidemic polio on America's war effort during World War II. The primary sources consulted include newspapers, military medical reports, photographs, memoirs, speeches, and archival collections. It looks at the effects of polio on the home front, more specifically how epidemics and the rising rates of polio were a detriment to the civilian war effort. It also focuses on the American military's preparation for and response to polio outbreaks among troops both at home and abroad. Finally, it discusses the experiences of the servicemen who contracted polio during the war. This work fills a major hole in the historiography of the disease and highlights the overlapping interests of the public, the medical community, and the military during a time of war.

Bacterial infections are a major cause of morbidity and mortality in both the community and nosocomial settings, particularly among the elderly and chronically ill. Sepsis is the body’s response to antigens and toxins released by the invasive pathogenic organisms that cause infection. When infection is not effectively controlled, sepsis may develop and progress to severe sepsis and septic shock. Early diagnosis and treatment is pivotal for survival in severe sepsis and particularly, septic shock. Our research focuses on developing a novel treatment strategy for septic shock by using single, ultra-high doses of aminoglycosides. In this project, the effect of a single, ultra-high dose of gentamicin in clearing bacteria from the blood and reducing the bacterial burden in vital organs was evaluated in a rat model of E. coli (Bort strain) induced peritonitis with severe sepsis/septic shock. Serum cytokine levels and serum lactate levels were serially measured. Further, the potential adverse effects of ultra-high dosing of aminoglycoside antibiotics in a short-term (9 h) invasive study and long term (180 days) non-invasive study were assessed. Neuromuscular paralyses due to ultra-high doses of aminoglycosides were assessed. In addition, renal injury markers such as serum creatinine and urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) were assayed. The auditory and vestibular function was also assessed after ultra-high dosing of aminoglycoside in the long-term study. We conclude that animals can tolerate ultra-high doses of aminoglycosides with appropriate support. Animals were under neuromuscular paralysis for 28 – 50 minutes and were on ventilator support after single ultra-high doses (80 and 160 mg/kg) of aminoglycoside antibiotics (gentamicin and tobramycin). There was no significant acute or delayed renal or ototoxicity associated with the single, ultra-high dose aminoglycoside therapy. Histology studies of the kidneys and the cochlea of single, ultra-high aminoglycoside dosed animals and untreated control animals were performed after 180 days (6 months). Results indicated that there were no morphological differences between the treated and untreated control animals. Terminal deoxy-nucleotidyl transferase dUTP nick end labeling (TUNEL) assay of kidney tissue indicated that there was no apoptosis of endothelial cells in the tubular and glomerular regions with single, ultra- high dose of aminoglycosides consistent with an absence of ultrahigh dose induced nephrotoxicity. In the septic shock model, the E. coli Bort was below the limit of detection from the blood of the animals within minutes after single, ultra-high dose aminoglycoside administration. After necropsy, bacterial load was determined from all the vital organs and peritoneal fluid (site of infection). The bacterial levels were below the detection limit from the kidneys and there was a significant reduction in bacterial counts from all the remaining organs compared to the infected control animals. A decrease in serum cytokine and serum lactate levels compared to baseline was observed after ultra-high doses of aminoglycosides in the septic shock animals. Our studies have indicated that the ultra-high dose gentamicin is well tolerated by rats. It is highly effective in clearing E. coli Bort from the blood and reducing the bacterial burden in the organs in an experimental model of bacterial peritonitis/septic shock. Further studies in larger animals such as rabbits, sheep, pigs or dogs are required to confirm these results. If these findings are replicated in larger animals, this therapy may be developed further from ‘lab to bedside’ to treat septic shock patients in intensive care units (ICUs). / October 2015

Les syndromes myotoniques congénitaux atypiques dus à des mutations du canal sodé voltage-dépendant Nav1.4 se distinguent des myotonies congénitales classiques (canal chlore ClC-1) par la présence de traits atypiques incluant des myotonies douloureuses aggravées au froid et à l’ingestion de potassium. La caractérisation clinique et moléculaire de plusieurs familles atteintes de ces conditions rares dans la région du Saguenay-Lac-St-Jean nous a permis de découvrir une nouvelle mutation SCN4A à effet fondateur causant un phénotype de myotonies douloureuses aggravées au froid, parfois accompagné de phénomènes dystrophiques ou paralytiques. L’ampleur de notre cohorte nous permet de commenter sur l’hétérogénité phénotypique observée, sur les traits caractéristiques des syndromes associés au gène SCN4A, sur les implications physiologiques probables d’une telle mutation ainsi que sur les facteurs modulant le phénotype observé. Enfin, notre étude nous permet de souligner l’importance du dépistage familial systématique afin de prévenir les complications anesthésiques potentielles associées à ces conditions. / Congenital myotonic syndromes due to mutations of the voltage-gated sodium channel Nav1.4 differ from those due to mutations of the chloride channel CLC-1 as they tend to present atypical traits including painful myotonias and aggravation of symptoms with cold and potassium ingestion. Indeed, after completing the clinical and molecular characterization of a large cohort of patients affected with these rare conditions in the Saguenay Lac-St-Jean area, we were able to describe a new founder SCN4A mutation presenting with painful cold-induced myotonias and occasional dystrophic and paralytic episodes. Our study illustrates the wide phenotypic variability and the typical traits of SCN4A mutations. In addition, we were able to speculate on the probable physiological consequences of such mutations. Finally, we conclude by stressing the importance of familial screening in order to reduce the incidence of anesthetic complications associated with these conditions.

Thesis "Care of ventilator-dependent patienl wilh spinal cord injury in Czech republic" deals with problems of high cervica\ spinal cord les ion wilh diaphragm para\ysis. Generally introduces clinical manifestation of the spinal cord injury, classifícation of spinal cord lesions and statistical data regarding the incidence, prevalence and etiology. In more detail focuses on respiratory problems. Contains survey of most conunon respiratory complications in ventilator-dependent quadriplegic patients and infonn about the possibililies of respiralory physiotherapy. The practical part provides the first description of the Czech population of pentaplegics. Truough case studies indroduces health and livíng conditíons of persons wíth high spinal cord lesion and need of mechanical ventilation. Powered by TCPDF (www.tcpdf.org)

A aplicação de toxina botulínica A no lado não paralisado (LNP) é feita para tratar a assimetria resultante da paralisia facial (PF). As unidades de toxina onabotulinica A (Ona) e toxina abobotulinica A (Abo) não são equivalentes. Comparou-se a taxa de conversão de 1:3 em pacientes com PF. Cinquenta e cinco pacientes (idade entre 16 e 67 anos, 43 mulheres), com PF de longa duração foram tratados de forma aleatória com a aplicação de Ona (n = 25) ou Abo (n = 30) no LNP. Efeitos adversos, simetria facial, satisfação subjetiva e Índice de Incapacidade Facial (IIF) foram avaliados após 1 e 6 meses. Os resultados mostraram que a incidência de efeitos adversos foi maior com Abo (93,3% vs. 64,0%, p = 0,007). Avaliação Clínica do LNP diminuiu após 1 mês e aumentou novamente aos 6 meses, sem diferenças entre os grupos. A nota do lado paralisado (LP) foi menor no grupo Ona antes do tratamento, mas semelhante em ambos os grupos depois do tratamento. A nota do LP aumentou depois de 1 mês, e aos 6 meses foi ainda maior que a nota de prétratamento em ambos os grupos. A avaliação subjetiva melhorou em todos os momentos em comparação com a nota do pré-tratamento e diferiu entre os dois grupos apenas em 1 mês, quando o grupo Abo ficou um pouco mais paralisado. Índice de Função Física (IFF) e Índice de Bem-Estar Social (IBES), subescalas do Índice de Incapacidade Facial (IFF), entre os dois grupos não foram diferentes. Concluímos que ambas as toxinas reduziram a assimetria de forma eficiente em pacientes com FP. Os efeitos adversos foram maiores com Abo na equivalência de 1:3 / Botulinum toxin A injection into the nonparalyzed side (NPS) is used to treat asymmetry resulting from facial palsy (FP). OnabotulinumtoxinA (ONA) and abobotulinumtoxinA (ABO) units are not equivalent. We compared the conversion ratio of 1:3 in patients with FP. Fifty-five patients (aged 16-67 years, 43 women) with long-standing FP were randomly treated with either ONA (n = 25) or ABO (n = 30) injections into the NPS. Adverse effects, facial symmetry, subjective satisfaction, and Facial Disability Index (FDI) were assessed after 1 and 6 months. The results showed that the incidence of adverse effects was higher with ABO (93.3% vs. 64.0%, p = 0.007). Clinical scores of the NPS decreased after 1 month and increased again at 6 months, with no betweengroup differences. Scores of the paralyzed side were lower in the ONA group before treatment, but similar in both groups thereafter. The paralyzed side scores increased after 1 month, and at 6 months were still higher than the pretreatment scores in both groups. Subjective assessment improved at all time points compared to pretreatment score and differed between the two groups only at 1 month, when the ABO group was a bit too paralyzed. The Physical Function and Social/Well-Being Function subscales of the FDI did not differ between the two groups. We conclude that both toxins efficiently reduced asymmetry in patients with FP. Adverse effects were higher with ABO at an equivalence ratio of 1:3

INTRODUÇÃO: A paralisia facial de longa duração cursa com déficit funcional e estético, responsáveis por distúrbios psicológicos e prejuízo na qualidade de vida. Mesmo técnicas cirúrgicas modernas de reanimação conseguem restabelecer apenas parcialmente a movimentação emocional e a simetria entre as hemifaces. A toxina botulínica tipo A provoca paralisia muscular flácida reversível, corrigindo desequilíbrios entre músculos agonistas hipoativos e antagonistas relativamente hiperativos. Não há na literatura séries padronizadas com mais de 10 pacientes com paralisia facial tratados por meio da aplicação de toxina botulínica no lado são a fim de obter maior simetria na dinâmica facial na região da boca. MÉTODOS: Este estudo prospectivo teve como objetivo avaliar o efeito do tratamento adjuvante com toxina botulínica no lado são de 25 pacientes com paralisia facial de longa duração, previamente tratados cirurgicamente. O tempo de seguimento foi de 6 meses. Foram métodos de avaliação escala clínica padronizada, grau de satisfação do paciente, Índices de Função Física (IFF) e de Bem-Estar Social (IBES) e eletromiografia de superfície. A dose total de toxina botulínica variou de 15 a 69 U, média 37,9 ± 5,4 U. Dezesseis pacientes apresentaram efeitos adversos com duração média de 14,1 ± 7,3 dias, incluindo dificuldade para articular palavras, beber, mastigar e se adaptar à redução do sorriso. RESULTADOS: 1) Houve redução significante da assimetria entre as hemifaces, de 48,4% após 1 mês e 16,8% aos 6 meses. O ganho de simetria após 1 mês ocorreu em decorrência da diminuição do movimento do lado são, combinada à melhora da avaliação do lado paralisado. Aos 6 meses, com a perda do efeito clínico da toxina botulínica, a nota do lado são voltou a ser semelhante à do pré-tratamento. A redução de assimetria nessa fase ocorreu devido à melhora significante do lado paralisado em relação ao pré-tratamento. 2) A avaliação subjetiva do paciente em relação à simetria apresentou aumento significante, 1 mês e 6 meses em relação ao pré-tratamento. 3) Houve aumento do IFF ao longo do tempo, porém não significante. O IBES apresentou aumento significante aos 6 meses, comparado ao pré-tratamento. 4) Um mês após a aplicação, o efeito da toxina botulínica levou à diminuição significante do potencial de ação do lado não-paralisado. Após 6 meses, o valor voltou a ser semelhante ao do pré-tratamento. CONCLUSÕES: O tratamento proposto permitiu, com técnica minimamente invasiva, obter melhor simetria facial estática, evidenciada pela posição do ângulo da boca, do filtro labial, dos sulcos nasogenianos, do nariz e do supercílio, e melhor simetria dinâmica, principalmente ao sorrir, falar, na exposição dos dentes e na movimentação facial como um todo. Mesmo após a perda do efeito clínico da droga aos 6 meses, houve 18% de melhora da avaliação clínica do lado paralisado em relação ao pré-tratamento, e melhora dos índices de satisfação e qualidade de vida dos pacientes. / INTRODUCTION: Long-standing facial paralysis presents with functional and aesthetic deficits, which are responsible for psychological disturbances and life quality impairment. Even after modern facial reanimation surgical techniques, the emotional movement and the symmetry of the hemifaces is only partially restablished. Botulinum toxin type A causes reversible flacid muscle paralysis, thus correcting imbalances among hypoactive agonists and relatively hyperactive antagonists. There are no standardized series in the literature with more than 10 facial paralysis patients treated with botulinum toxin injection in the non-paralysed side in the mouth area, with the objective of obtaining better dynamic facial symmetry. METHODS: This prospective study had the objective of evaluate, with 6 months follow-up, the effects of the adjuvant treatment using botulinum toxin in the healthy hemiface of 25 patients with long-standing facial paralysis, previously treated surgically. The methods of evaluation were a standardized clinical scale, the patients degree of satisfaction, the Physical Function and Social/well-being Function subscales of the Facial Disability Index and surface electromyography. Total botulinum toxin dose varied from 15 to 69 U, mean 37,9 ± 5,4 U. Sixteen patients presented adverse effects with mean duration time 14,1 ± 7,3 days, including difficulty in speaking, drinking, eating and adapting to the reduced smile. RESULTS: 1) There was significant reduction of facial asymmetry, of 48,4% at 1 month and of 16,8% at 6 months post-treatment. The better symmetry 1 month post-treatment was consequent to reduced movement on the non-paralysed side combined to better evaluation on the paralysed side. At 6 months, the non-paralysed side had similar grading than that of pre-treatment, showing absence of clinical effect of the toxin. At this time, the asymmetry reduction was due to significant increase in the evaluation of the paralysed side in relation to the pre-treatment. 2) Patients satisfaction with facial symmetry showed significant increase, 1 month and 6 months post-treatment. 3) The Physical Function Index increased, but not significantly. The Social/well-being Function Index showed significant increase at 6 months compared to pre-treatment. 4) There was significant decrease in the action potential of the non-paralysed side one month post-injection of the botulinum toxin. After 6 months, the value returned to baseline. CONCLUSIONS: The proposed treatment allowed, with minimally invasive technique, better facial symmetry at rest, evidenced by better mouth, nose and brow position, and on facial movement as a whole, especially when smiling, speaking or exposing teeth. Even after the loss of the clinical effect of the drug at 6 months, there was an 18% increase in the clinical evaluation of the paralysed side in relation to pre-treatment, and increase in the satisfaction and quality of life indexes.